← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Orphagen Pharmaceuticals
San Diego, CA
$11,672,589
Total funding
21
Grants
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,672,589 · 21
By mechanism
R44$6,689,973 · 4
R43$4,843,366 · 15
R21$70,000 · 1
R03$69,250 · 1
Investigators at Orphagen Pharmaceuticals
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer$1,306,362
R44 · FY2021 · CA
Translational feasibility of an oral, non-hormonal, male contraceptive pill$1,093,784
R44 · FY2019 · HD
A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells$1,078,081
R44 · FY2024 · DK
Translational feasibility of an oral, non-hormonal, male contraceptive pill$719,059
R44 · FY2020 · HD
Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer$693,171
R44 · FY2022 · CA
A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells$634,145
R44 · FY2025 · DK
Novel CNS Target for Sleep-Wake and Psychiatric Disorders$481,388
R44 · FY2010 · MH
Novel CNS Target for Sleep-Wake and Psychiatric Disorders$479,791
R44 · FY2009 · MH
Inhibitor of Adrenal Steroid Synthesis for Cancer Treatment$400,027
R43 · FY2010 · CA
Feasibility Study of Novel Drug Target for Multiple Sclerosis$303,596
R43 · FY2007 · NS
Thymocyte Drug Target of Immune Reconstitution$270,181
R43 · FY2004 · AI
Small Molecule Inhibitors of Effector Th-17 Cells in Inflammatory Bowel Disease$266,559
R43 · FY2008 · DK
Small molecule target for suppression of autoimmunity in rheumatoid arthritis$258,166
R43 · FY2007 · AR
Neural Stem Cell-Selective Drug Target for Small Molecule Therapy of Brain Tumors$250,507
R43 · FY2012 · CA
Adrenal Androgen Blockade for Metastic Prostate Cancer$249,900
R43 · FY2003 · CA
Adrenal Androgen Blockade for Metastic Prostate Cancer$249,846
R43 · FY2004 · CA
Small Molecule Ligand Discovery for Sleep Cycle Disorders$233,571
R43 · FY2005 · MH
Small Molecule Ligand Discovery for Sleep Cycle Disorders$226,768
R43 · FY2006 · MH
Orphan Nuclear Receptor as Novel Drug Discovery Target for Cancer Immunotherapy$224,954
R43 · FY2015 · CA
Pharmacological Suppression of Rod Opsin as Therapy for Retinitis Pigmentosa$224,474
R43 · FY2013 · TR